Sign in

    Alan Young

    Senior Equity Analyst at Jefferies

    Alan Young is a Senior Equity Analyst at Jefferies, specializing in coverage of companies within the healthcare and biotechnology sectors. He tracks prominent firms such as Moderna, BioNTech, and Gilead Sciences, consistently delivering performance that places him among the top quartile of Wall Street analysts, as measured by platforms like TipRanks, with a success rate around 65% and average annualized returns exceeding 10%. Young began his analyst career in the early 2010s, previously working at Citi and Leerink Partners before joining Jefferies in 2018. He holds FINRA Series 7, 63, and 86/87 registrations and has been recognized for insightful coverage and institutional client impact.

    Alan Young's questions to DAQO NEW ENERGY (DQ) leadership

    Alan Young's questions to DAQO NEW ENERGY (DQ) leadership • Q2 2025

    Question

    Alan Young of Jefferies asked about the rationale and timeline for the newly announced $100 million share repurchase program. He also questioned if the company would consider selling its A-shares to fund the US buyback and what Daqo's production volume might look like if industry consolidation is successful.

    Answer

    Deputy CEO Anita Zhu stated the buyback reflects optimism about an industry turning point and is intended to strengthen shareholder confidence. She confirmed that selling A-shares to fund the US buyback is 'definitely back on the table.' Regarding future production, she explained that post-consolidation, all companies would likely operate at utilization rates that match annual demand, implying rates below 100%.

    Ask Fintool Equity Research AI